+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987005
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4


  • AbbVie Inc
  • Cipla, Inc
  • F. Hoffmann-La Roche, Ltd
  • Gilead Sciences, Inc
  • Hetero Healthcare Limited
  • LAURUS Labs
  • MORE
The Hepatitis Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period. Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver and liver failure, which can be fatal.

Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.

According to the World Health Organization (WHO), globally, 500 million people are estimated to be infected with hepatitis B or C. About 1.5 million people die in a year due to hepatitis infection, 1 in every 3 people get infected and most of the infected people do not know about it due to dormant symptoms. In addition, in European Hepatitis B and C affect millions of people. In addition, According to the European Centre for Disease Prevention and Control (ECDC), estimates an overall incidence of hepatitis B is 1.49 (Per 100,000), hepatitis c is 8.7 (Per 100,000) in the member states of the European Union (EU) and high prevalence in people who inject drugs.

An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market.

Key Market Trends

Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market
  • Hepatitis C is a liver infection which is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Acute hepatitis C occurs within the first 6 months after individual is exposed to the hepatitis C virus and chronic hepatitis C can be a lifelong infection with the hepatitis C virus if left untreated.
  • According to World Health Organization (WHO), hepatitis C virus (HCV) infection affects over 70 million people globally, and about 3.5 million Americans have hepatitis C virus (HCV) infection among them approximately 3.2 million have chronic (long-term) infection.
  • Hepatitis C segment holds a significant market share in the hepatitis therapeutics market and is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions and the growing availability of effective drug regimens in the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC), estimates about 2.4 million people are living with hepatitis C in the United States and approximately 850,000 people in this region estimated to be living with hepatitis B. In addition, 67% of persons infected with hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advance therapeutics and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited and Cipla, Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie Inc
  • Cipla, Inc
  • F. Hoffmann-La Roche, Ltd
  • Gilead Sciences, Inc
  • Hetero Healthcare Limited
  • LAURUS Labs
  • MORE
1.1 Study Assumptions
1.2 Scope of the Study




4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Viral Hepatitis
4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
4.3 Market Restraints
4.3.1 Stringent Regulatory Issues
4.3.2 Poor Reimbursement Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5.1 By Disease Type
5.1.1 Hepatitis A
5.1.2 Hepatitis B
5.1.3 Hepatitis C
5.1.4 Hepatitis D
5.1.5 Other Types
5.2 By Drug Class
5.2.1 Interferon
5.2.2 Monoclonal Antibody
5.2.3 Non-structural protein 5A (NS5A) inhibitors
5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
5.2.6 Multi Class Combination
5.2.7 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle East-and Africa
5.3.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles
6.1.1 Merck & Co., Inc
6.1.2 Gilead Sciences, Inc
6.1.3 AbbVie Inc
6.1.4 Bristol Myers Squibb Company
6.1.5 F. Hoffmann-La Roche, Ltd
6.1.6 LAURUS Labs
6.1.7 Zydus Cadila
6.1.8 Hetero Healthcare Limited
6.1.9 NATCO Pharma Limited
6.1.10 Cipla, Inc

Note: Product cover images may vary from those shown
3 of 4
  • Merck & Co., Inc
  • Gilead Sciences, Inc
  • AbbVie Inc
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche, Ltd
  • LAURUS Labs
  • Zydus Cadila
  • Hetero Healthcare Limited
  • NATCO Pharma Limited
  • Cipla, Inc
Note: Product cover images may vary from those shown
4 of 4